Joris L. Vos

916 total citations · 1 hit paper
14 papers, 232 citations indexed

About

Joris L. Vos is a scholar working on Oncology, Surgery and Otorhinolaryngology. According to data from OpenAlex, Joris L. Vos has authored 14 papers receiving a total of 232 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Surgery and 4 papers in Otorhinolaryngology. Recurrent topics in Joris L. Vos's work include Cancer Immunotherapy and Biomarkers (8 papers), Head and Neck Cancer Studies (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). Joris L. Vos is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Head and Neck Cancer Studies (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). Joris L. Vos collaborates with scholars based in Netherlands, United States and Germany. Joris L. Vos's co-authors include Charlotte L. Zuur, Joleen J.H. Traets, Lodewyk F.A. Wessels, Annegien Broeks, John B.A.G. Haanen, Iris Mimpen, Joris van de Haar, Gijs F. de Wit, Sten Cornelissen and Edwin Cuppen and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Joris L. Vos

13 papers receiving 229 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A pan-cancer analysis of the microbiome in metastatic cancer

2024 94 citations Thomas Battaglia, Iris Mimpen et al. Cell profile →

Peers

Joris L. Vos

ONCOL

OTORH

SURGE

IMMUN

C. Codecà Italy

Maria Renata Sales Nogueira Brazil

Andrew Sewell United States

Shintaro Tsukinaga Japan

Mattias Jangard Sweden

Preetha Chengot United Kingdom

Fangjia Tong China

F. Moreau France

Atsuko Hirai Japan

N Würdemann Germany

C. Codecà Italy

Joris L. Vos

78 ×0.7

ONCOL

56 ×0.9

67 ×1.3

OTORH

37 ×0.7

SURGE

15 ×0.3

IMMUN

Citations per year, relative to Joris L. Vos Joris L. Vos (= 1×) peers C. Codecà

Countries citing papers authored by Joris L. Vos

Since Specialization

Citations

This map shows the geographic impact of Joris L. Vos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joris L. Vos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joris L. Vos more than expected).

Fields of papers citing papers by Joris L. Vos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joris L. Vos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joris L. Vos. The network helps show where Joris L. Vos may publish in the future.

Co-authorship network of co-authors of Joris L. Vos

This figure shows the co-authorship network connecting the top 25 collaborators of Joris L. Vos. A scholar is included among the top collaborators of Joris L. Vos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joris L. Vos. Joris L. Vos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Vos, Joris L., Stanley Z. Lam, Catherine Y. Han, et al.. (2025). Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination. Nature Genetics. 57(6). 1504–1511. 1 indexed citations

Valero, Cristina, Joris L. Vos, Alex A. Adjei, et al.. (2025). Neutrophil to lymphocyte ratio varies in magnitude and biomarker utility based on patient demographics. Journal of Clinical Investigation. 136(1).

Vos, Joris L., Joleen J.H. Traets, Xiaohang Qiao, et al.. (2024). Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma. JCI Insight. 9(21). 5 indexed citations

Gil-Jimenez, Alberto, Nick van Dijk, Joris L. Vos, et al.. (2024). Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors. Nature Communications. 15(1). 2538–2538. 10 indexed citations

Lei, Xin, Marij J.P. Welters, Ellen Schrama, et al.. (2024). CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors. Cellular and Molecular Immunology. 21(4). 374–392. 27 indexed citations

Battaglia, Thomas, Iris Mimpen, Joleen J.H. Traets, et al.. (2024). A pan-cancer analysis of the microbiome in metastatic cancer. Cell. 187(9). 2324–2335.e19. 94 indexed citations breakdown →

Desîlets, Antoine, Joris L. Vos, Nora Katabi, et al.. (2024). Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma. Clinical Cancer Research. 30(23). 5281–5292. 2 indexed citations

Lee, Andrew S., Cristina Valero, Seong‐Keun Yoo, et al.. (2023). Validation of a Machine Learning Model to Predict Immunotherapy Response in Head and Neck Squamous Cell Carcinoma. Cancers. 16(1). 175–175. 1 indexed citations

Leun, Anne M. van der, Joleen J.H. Traets, Joris L. Vos, et al.. (2023). Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment. Cancer Discovery. 13(10). 2212–2227. 15 indexed citations

10.

Vos, Joris L., Renaud Tissier, Laura A. Smit, et al.. (2022). Quantitative Diffusion-Weighted Imaging Analyses to Predict Response to Neoadjuvant Immunotherapy in Patients with Locally Advanced Head and Neck Carcinoma. Cancers. 14(24). 6235–6235. 9 indexed citations

11.

Vos, Joris L., Charlotte L. Zuur, Laura A. Smit, et al.. (2021). [18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 49(6). 2010–2022. 23 indexed citations

12.

Vos, Joris L., Joris B.W. Elbers, Oscar Krijgsman, et al.. (2020). LBA40 Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial. Annals of Oncology. 31. S1169–S1169. 13 indexed citations

13.

Zuur, Charlotte L., Joris B.W. Elbers, Joris L. Vos, et al.. (2019). Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).. Journal of Clinical Oncology. 37(15_suppl). 2575–2575. 12 indexed citations

14.

Vos, Joris L., et al.. (2017). Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients. European Archives of Oto-Rhino-Laryngology. 274(12). 4121–4126. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact